CORE--IMMUNOLOGY

核心--免疫学

• 批准号: 6358017
• 负责人: NARENDRA CHIRMULE
• 金额: $ 19.18万
• 依托单位: UNIVERSITY OF PENNSYLVANIA
• 依托单位国家: 美国
• 财政年份: 2000
• 资助国家: 美国
• 起止时间: 2000-09-01 至 2001-08-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/6358017
• 关键词: CD4 molecule; antibody neutralization test; biomedical facility; cell mediated lymphocytolysis test; cellular immunity; enzyme linked immunosorbent assay; gene therapy; helper T lymphocyte; humoral immunity; immunologic assay /test; transfection /expression vector; virus antigen; western blottings

Immune responses to gene therapy are important considerations in the development of effective vectors. In vivo delivery of recombinant adenoviruses have established important principles likely to be relevant to many other systems. Humoral immune responses develop to the capsid proteins of the input virus, which diminish the efficiency of vector readministration. Adenoviruses deleted of the E1 genes express viral proteins in the transduced cell, which activate destructive cytotoxic T lymphocytes (CTLs). Frequently, the transgene product can serve as a target for CTL, as well. Dr. Naren Chirmule was recruited to the Institute for Human Gene Therapy (IHGT) in 1996 to establish a core facility in immunology. This Core provides a large profile of an in vitro assays to measure cellular and humoral immune responses to vectors and transgene products. Included are analyses of CD4+ T cells (lymphoproliferation and cytokine release assays) as well as chromium release assays to assess CTLs. Humoral immune responses are measured through ELISA, Western Blots, isotype fractionation, and neutralizing assays. Viral and transgene products are evaluated as potential antigens in these assays. The Immunology Core provides full service to P30 investigators in areas of basic, translational, and clinical research. The core is a useful mechanism to assure standardization of assays across different protocols.

对基因疗法的免疫反应是重要的考虑因素 开发有效的向量。重组体内递送 腺病毒已经建立了可能相关的重要原则 到许多其他系统。体液免疫反应发展为CAPSID 输入病毒的蛋白质，从而降低了载体的效率 重新管理。 E1基因删除的腺病毒表达病毒 转导细胞中的蛋白质，激活破坏性细胞毒性T 淋巴细胞（CTL）。通常，转基因产品可以用作 也是CTL的目标。 Naren Chirrule博士被招募到该研究所 1996年人类基因疗法（IHGT）建立了核心设施 免疫学。该核心提供了大量的体外测定法 测量对向量和转基因的细胞和体液免疫反应 产品。包括CD4+ T细胞的分析（淋巴增生和 细胞因子释放分析）以及评估铬释放分析 CTL。通过ELISA，Western印迹， 同种型分馏和中和测定。病毒和转基因 在这些测定中将产品评估为潜在抗原。这 免疫学核心为P30调查人员提供全面服务 基础，翻译和临床研究。核心是有用的 确保跨不同方案的测定标准化的机制。